FEDERAL TRADE COMMISSION v. ENDO PHARMACEUTICALS INC. et al
Case Number:
1:21-cv-00217
Court:
Nature of Suit:
Judge:
Firms
Companies
Government Agencies
Sectors & Industries:
-
March 24, 2022
Endo Wins Dismissal Of FTC's Suit Over Impax Opioid Deal
Endo Pharmaceuticals on Thursday secured a D.C. federal court's dismissal of the Federal Trade Commission's antitrust suit accusing it of entering a second "pay-for-delay" agreement with Impax Laboratories to stave off competition to Endo's Opana ER painkiller.
-
June 11, 2021
Endo Can't Shake FTC Pay-For-Delay Suit, Judge Told
The Federal Trade Commission fought a dismissal bid Friday in an antitrust suit related to an alleged 2017 "pay-for-delay" agreement over Endo Pharmaceuticals' Opana ER painkiller, saying the drugmaker couldn't have made such an agreement because its competitor had already had a broad patent license for similar products for years.
-
April 27, 2021
Endo Says FTC Is Overreacting To Latest Impax Opioid Deal
Endo Pharmaceuticals is pushing for the dismissal of a Federal Trade Commission antitrust suit alleging it entered a second "pay-for-delay" agreement with Impax Laboratories over Endo's Opana ER painkiller, arguing the Patent Act and antitrust laws allow it to license its opioids to whomever it wants while excluding the competition.
-
January 25, 2021
FTC Says Endo, Impax Cut 2nd Opana ER Pay-For-Delay Deal
The Federal Trade Commission filed a new antitrust complaint Monday accusing Endo Pharmaceuticals and Impax Laboratories of striking a second deal to stave off competition to the Opana ER opioid pain medication even as an earlier FTC enforcement action over the same drug was moving forward.